Evidence map›Paper›PMID 41009713›Full record

ReviewInternational journal of molecular sciences2025

Exosome-like Nanoparticles Extracted from Plant Cells for Diabetes Therapy.

Xin Xiao, Yuliang Guo, Nontokozo Zimbili Msomi, Md Shahidul Islam, Maoquan Chu

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin XiaoSchool of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Yuliang GuoSchool of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
Nontokozo Zimbili MsomiDepartment of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, Pietermaritzburg 3209, South Africa.ORCID 0000-0003-2849-7533
Md Shahidul IslamDepartment of Biochemistry, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa.ORCID 0000-0003-0309-9491
Maoquan ChuSchool of Life Sciences and Technology, Tongji University, Shanghai 200092, China.

Funding

Shanghai Pujiang Program of the Shanghai Magnolia Talent Plan 24PJA132
6 · The paper itself

Abstract

Diabetes mellitus (DM) is a complex metabolic disorder characterized by chronic hyperglycemia and associated complications such as cardiovascular disease, nephropathy, retinopathy, neuropathy, and chronic non-healing wounds. Current antidiabetic therapies offer only partial glycemic control and are limited by poor bioavailability, adverse effects, and an inability to prevent disease progression. Plant-derived exosome-like nanoparticles (PENPs) have emerged as a promising class of natural nanocarriers with excellent biocompatibility, low immunogenicity, and intrinsic multi-component bioactivity. However, few reviews have addressed recent progress in PENPs for DM therapy. To capture the recent developments in this area, this review provides a systematic synthesis of recent advances in PENPs for DM therapy, covering plant sources, extraction and purification methods, molecular compositions, and therapeutic mechanisms. Preclinical studies have demonstrated that PENPs can improve hyperglycemia, enhance insulin sensitivity, regulate hepatic lipid metabolism, and promote wound healing by modulating oxidative stress, inflammation, gut microbiota, glucose metabolism, and insulin signaling. Additionally, PENPs have been shown to promote angiogenesis via glycolytic reprogramming. Despite these promising findings, challenges including scalable isolation, standardized physicochemical characterization, and clinical translation remain. Future directions include engineering multifunctional PENPs, establishing Good Manufacturing Practice (GMP)-compliant production, and conducting clinical trials to facilitate their integration into precision therapeutics for diabetes management.

Indexed as

Diabetes MellitusExosomesHypoglycemic AgentsNanoparticlesPlantsAnimalsHumansHypoglycemic Agentsdiabetes and its complicationsnanobiomedicinenatural nanocarriersplant-derived exosome-like nanoparticlesprecision therapy

Identifiers

PMID41009713
PMCPMC12470572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.